News

Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1
ClearBridge Investments, an investment management company, released its “ClearBridge Value Strategy” first quarter 2025 ...
STAT5d
Gilead is urged to rework licensing deals for groundbreaking HIV prevention drug
A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...
STAT13d
Rollout of ‘miracle’ HIV prevention drug is threatened by Trump cuts to global AIDS relief program
PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...
Fierce Pharma1d
Gilead reprimanded after PMCPA finds conference Wi-Fi sponsorship broke advertising rules
Gilead Sciences’ sponsorship of a conference Wi-Fi network has landed it in hot water. | Gilead Sciences’ sponsorship of a conference Wi-Fi network has landed it in hot water. The PMCPA ruled the ...
Investing27d
Gilead Sciences’ SWOT analysis: HIV giant’s stock faces pivotal transition
Gilead Sciences stands at a crossroads, balancing its established HIV franchise with emerging opportunities in oncology and other therapeutic areas. The success of lenacapavir in PrEP and the ...
AllAfrica on MSN4d
South Africa: The 6-Monthly Anti-HIV Jab Could End Aids in South Africa by 2032
A modelling study shows the six-monthly anti-HIV jab, lenacapavir, could end Aids in SA by 2032 — but only if between two and ...
Investing27d
Gilead Sciences’ SWOT analysis: HIV giant’s stock faces pivotal transition
Gilead Sciences stands at a crossroads, balancing its established HIV franchise with emerging opportunities in oncology and other therapeutic areas. The success of lenacapavir in PrEP and the ...